MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Accrued trade discountsand rebates$6,256K Accounts payable$4,250K Stock-based compensation$4,140K Amortization of intangibleassets$2,710K Net income (loss)$2,234K Amortization of debt discountand debt issuance...$889K Inventory-$851K Depreciation$337K Amortization of operatingright-of-use assets$163K Prepaid expenses andother current assets-$145K Net cash provided by(used in) operating...$9,870K Canceled cashflow$12,105K Net increase(decrease) in cash, cash...$708K Canceled cashflow$9,162K Trade accountsreceivable$5,245K Other-$4,683K Other accruedliabilities-$1,497K Operating leaseliabilities-$434K Accrued returns reserve-$246K Proceeds from issuance ofwarrants$7,333K Proceeds from exercise ofstock options$847K Net cash used infinancing activities-$8,837K Net cash used ininvesting activities-$325K Canceled cashflow$8,180K Repurchase of common stockwithheld for taxes$17,017K Capital expenditures-$325K
Cash Flow

Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings, Inc. (XERS)

source: myfinsight.com